Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Primary Outcome Measures:
- To compare the progression free survival(PFS) in patients with unresectable hepatocellular
carcinoma(HCC) treated with transcatheter arterial chemoembolization(TACE) with or without
Huachansu, and the correlation between PFS and expression of peripheral Na+/K+-ATPase α3
family.
Secondary Outcome Measures:
- To compare the overall survival(OS), objective response rate(ORR), and side effects of
treating HCC with TACE plus Huachansu or TACE alone.
Exploratory Outcome Measures:
- To evaluate the correlation between prognosis and expression of peripheral Na+/K+-ATPase α3
family.